Synovus Financial’s Seres Therapeutics MCRB Stock Holding History

Synovus Financial’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-25	Closed	-$2K	–	1139
2020 Q2	$2K	Hold	25	–	–	﹤0.01%	1433
2020 Q1	$2K	Sell	25 -2	-7%	-$134	﹤0.01%	1959
2019 Q4	$2K	Sell	27 -37	-58%	-$2.74K	﹤0.01%	1430
2019 Q3	$5K	Hold	64	–	–	﹤0.01%	1287
2019 Q2	$5K	Hold	64	–	–	﹤0.01%	1222
2019 Q1	$9K	Hold	64	–	–	﹤0.01%	1131
2018 Q4	$5K	Hold	64	–	–	﹤0.01%	1197
2018 Q3	$10K	Hold	64	–	–	﹤0.01%	1124
2018 Q2	$10K	Hold	64	–	–	﹤0.01%	1058
2018 Q1	$10K	Buy	+64	New	+$12.3K	﹤0.01%	1039
2017 Q2	–	Sell	-64	Closed	-$15K	–	979
2017 Q1	$15K	Hold	64	–	–	﹤0.01%	904
2016 Q4	$13K	Hold	64	–	–	﹤0.01%	892
2016 Q3	$15K	Buy	64 +37	+137%	+$13K	﹤0.01%	844
2016 Q2	$16K	Hold	27	–	–	﹤0.01%	788
2016 Q1	$14K	Hold	27	–	–	﹤0.01%	805
2015 Q4	$18K	Hold	27	–	–	﹤0.01%	779
2015 Q3	$16K	Buy	+27	New	+$22K	﹤0.01%	760

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Synovus Financial's MCRB Position: Q3 2020 in Review

Synovus Financial sold out of Seres Therapeutics (MCRB) in Q3 2020, closing a stake of 25 shares — an estimated $2K sold.

Synovus Financial first reported a position in MCRB in Q3 2015 and held it in 17 quarters. The position peaked at $18K in Q4 2015. 113 funds tracked by Wall St. Rank hold MCRB as of Q3 2020.

Synovus Financial reported no remaining Seres Therapeutics position as of Q3 2020 after selling out during the quarter.
Synovus Financial sold 25 Seres Therapeutics shares in Q3 2020, an estimated $2K.
Synovus Financial first reported a position in Seres Therapeutics in Q3 2015 and held it in 17 quarters.
Synovus Financial's Seres Therapeutics position peaked at $18K in Q4 2015.
113 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2020.

Based on Synovus Financial's 13F filing for Q3 2020, filed 9 Nov 2020.